{"id":396139,"date":"2020-12-09T07:03:24","date_gmt":"2020-12-09T12:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396139"},"modified":"2020-12-09T07:03:24","modified_gmt":"2020-12-09T12:03:24","slug":"fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/","title":{"rendered":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Event will review the company\u2019s novel approach to inducing fetal hemoglobin <\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Live webcast on December 15, 2020 at 8:30am ET<\/em>\n      <\/p>\n<p align=\"left\">CAMBRIDGE, Mass., Dec.  09, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E3IIuVlQ-SmZmIxfT9v9rQPzi0EYuZzFZKA06JKwOXzMmHpnIyqvkVTd6v3E5NJGHCMGr5r-DpNT2WvvnRNO0R-07xe5Tjle8VNCvcN8x4CYLYTXQCv27l3K98TpLi2-yrZWexK7wCUiRwUOTs8Cn74r47zD-bSrHhxB6bbjNmhUVF6ieCisgHAhfp0aO-nAkQesKYe92HMMse-ZPizdEh5q9c6ypjtIuLQdM7-w8xDqdE-l7MQNq-7RA-TXPdXcnT5fobI35TuQADAUYp2yyQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>Fulcrum Therapeutics, Inc.<\/strong><\/a>\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Tuesday, December 15, 2020 from 8:30am \u2013 10:00am ET to discuss the company\u2019s program with FTX-6058 for select hemoglobinopathies, including sickle cell disease and beta-thalassemia.<\/p>\n<p>Dr. Maureen Achebe and Dr. Gerd Blobel will join senior executives from Fulcrum in presenting and discussing sickle cell disease, the treatment landscape and the FTX-6058 program followed by a Question and Answer session. Maureen Achebe, MD is currently Clinical Director, Non-Malignant Hematology Clinic, Assistant Director, Brigham and Women\u2019s Hospital Outpatient Infusion Center, Director, Brigham and Women\u2019s Hospital Sickle Cell Program and Assistant Professor of Medicine, Harvard Medical School. Gerd Blobel, MD, PhD is currently Frank E. Weise III professor of pediatrics, University of Pennsylvania and Co-director Epigenetics Institute. He also holds the Frank E. Weise III Endowed Chair of Pediatrics at The Children\u2019s Hospital of Philadelphia and the Perelman School of Medicine.<\/p>\n<p>The live webcast will be accessible through the Investor Relations section of the company\u2019s website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Ha4wYfaEjN-Mgu9gwQ9bCO9Cbuae58Oqh2_Oiq0xgHTkTJvBEBB8jMy9HNcWQaRoaiLF7xEYmeyxH2Kqqz-zeZHWiDiyIdl-aZCzDo76mFadE2mUgZt5zReTLRqX1wEWufmRa5lSRq0WoRPvsjzqQT04WaB1GEN4XjTmpKlF3Se43bEFcFJDptZJopPokhSYkWA3FEHQQ4dnySsUlwIukhhWwykcGY3a7TsZqLgrfJJohz5AhCf7ydq9GMWyONxnenmRgEW2Wrz6Rhh-uMO9MW-GMsGb2vqkQEaqApCuTd7mbhhNFU59bLNcxZNVZFlRUwGKntFcArxctj09HlIbFkLWSVPIaARpVAi-J6BAmiDRK8CbiSQ9HEAIVwGXi15\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.fulcrumtx.com\/events-and-presentations<\/a>. Following the live webcast, an archived replay will also be available on the website for up to 90 days.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>FTX-6058<\/strong><br \/>\n        <br \/>FTX-6058 is a highly potent small molecule inhibitor of EED capable of inducing robust HbF protein expression in cell and murine models. Fulcrum believes the pharmacokinetics and human dose simulations support that FTX-6058 may be given as a once daily oral compound. The validation of EED as a target for sickle cell disease and the discovery of FTX-6058 as a novel HbF-inducing small molecule were conducted using Fulcrum\u2019s proprietary Product Engine. The company\u2019s composition of matter patent covering FTX-6058 and related structures has been granted. Preclinical data with FTX-6058 showed an increase in HbF levels up to approximately 30% of total hemoglobin. Fulcrum has initiated a Phase 1 trial with FTX-6058 in healthy volunteers.<\/p>\n<p>\n        <strong>About Fulcrum Therapeutics<\/strong>\u00a0<br \/>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum\u2019s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia, into Phase 1 clinical development.<\/p>\n<p>Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ncxiTh5ce3Lxvq4FEIPUs9eHu0vDX7uuvdc3buQYP1FjZQECSZo7ZzDEqonSOEuy7d3v-rH_BKcOALKoc-QwEA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fulcrumtx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company\u2019s product candidates and the potential advantages and therapeutic potential of the Company\u2019s product candidates. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company\u2019s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum\u2019s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; initiate and enroll clinical trials on the timeline expected or at all; correctly estimate the potential patient population and\/or market for the Company\u2019s product candidates; replicate in later clinical trials positive results found in preclinical studies and\/or earlier-stage clinical trials of losmapimod and its other product candidates; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company\u2019s actual results to differ from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in the Company\u2019s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company\u2019s views as of the date hereof and should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company\u2019s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.<\/p>\n<p>\n        <strong>C<\/strong><br \/>\n        <strong>ontact:<\/strong>\n      <\/p>\n<p>Investors:<br \/>Christi Waarich<br \/>Director, Investor Relations and<br \/>Corporate Communications <br \/>617-651-8664<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J5NvtXjPPx_OlgoOYIe4VDISrvHdlP6xDim6l8LDlvMvGvjUDhefkLGiPVo5Q4AvTtOqj6PaFMDiNZPa6k4D-C4nV4cBoOHA8p-ptiWwoMQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cwaarich@fulcrumtx.com<\/a><\/strong><\/p>\n<p>Stephanie Ascher <br \/>Stern Investor Relations, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kXFbMtDdu7_htsPbF6kUsFIbl_TRMaazJcZ5rghPNbqC61p8hmnRsPHWeQjmBAG4uCH8DuD8Uby9IWLJZrxtrmhdjzkaEQltXDbsPAjwHwrcPIMlAHXSyBWW-s4Pa9kY\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>stephanie.ascher@sternir.com<\/u><\/strong><\/a><br \/>212-362-1200<\/p>\n<p>Media: <br \/>Kaitlin Gallagher<br \/>Berry &amp; Company Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A9IUOVwlMqk96FHV3eewMOI2SmtA24zoxv64kQaQ_bXXpz32Uv2qbNpAZpzeFT4TZasLgwrCQxHy8v_b6i2E_3_XiF4ZFpnB7pAYeyLc27M=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>kgallagher<\/u><\/strong><strong><u>@berrypr.com<\/u><\/strong><\/a><br \/>212-253-8881<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/aada171b-e598-44fb-8259-cee108f4fe9d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Event will review the company\u2019s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Tuesday, December 15, 2020 from 8:30am \u2013 10:00am ET to discuss the company\u2019s program with FTX-6058 for select hemoglobinopathies, including sickle cell disease and beta-thalassemia. Dr. Maureen Achebe and Dr. Gerd Blobel will join senior executives from Fulcrum in presenting and discussing sickle cell disease, the treatment landscape and the FTX-6058 program followed by a Question and Answer session. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Event will review the company\u2019s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Tuesday, December 15, 2020 from 8:30am \u2013 10:00am ET to discuss the company\u2019s program with FTX-6058 for select hemoglobinopathies, including sickle cell disease and beta-thalassemia. Dr. Maureen Achebe and Dr. Gerd Blobel will join senior executives from Fulcrum in presenting and discussing sickle cell disease, the treatment landscape and the FTX-6058 program followed by a Question and Answer session. &hellip; Continue reading &quot;Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease\",\"datePublished\":\"2020-12-09T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/\"},\"wordCount\":955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/\",\"name\":\"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\",\"datePublished\":\"2020-12-09T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/","og_locale":"en_US","og_type":"article","og_title":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk","og_description":"Event will review the company\u2019s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Tuesday, December 15, 2020 from 8:30am \u2013 10:00am ET to discuss the company\u2019s program with FTX-6058 for select hemoglobinopathies, including sickle cell disease and beta-thalassemia. Dr. Maureen Achebe and Dr. Gerd Blobel will join senior executives from Fulcrum in presenting and discussing sickle cell disease, the treatment landscape and the FTX-6058 program followed by a Question and Answer session. &hellip; Continue reading \"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T12:03:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease","datePublished":"2020-12-09T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/"},"wordCount":955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/","name":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=","datePublished":"2020-12-09T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTEzNSMzODYyOTk5IzIxODM1NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickle-cell-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}